Published in Drug Law Weekly, June 28th, 2005
Insmed and Avecia had made motions for summary judgment in each matter. Their motions attacked the validity of the Tercica/Genentech patent at issue. The court ruled in Tercica's and Genentech's favor in denying both motions. The court also ordered Insmed and Avecia to pay Tercica's and Genentech's legal fees.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.